Praveen Kammar, Director at Specialty Surgical Oncology Hospital and Research Center, shared on LinkedIn:
“PERISCOPE II: Does CRS-HIPEC Have a Role in Gastric Cancer With Limited Peritoneal Metastases?
The recently published PERISCOPE II trial adds important randomized evidence to this ongoing debate.
In 102 patients with limited peritoneal metastases (PCI <7) and/or positive peritoneal cytology, gastrectomy + CRS-HIPEC failed to demonstrate an overall survival benefit over continued systemic therapy.
Key findings:
- Median OS: 15.7 vs 16.6 months (HR 1.10; p=0.70)
- Grade ≥3 adverse events: 42% vs 20%
- Three treatment-related deaths in the experimental arm.
However, the trial raises important questions.
It was stopped prematurely, patient numbers were small, treatment crossover occurred, and a substantial proportion of patients assigned to CRS-HIPEC never underwent the procedure.
The per-protocol analysis numerically favoured CRS-HIPEC (HR 0.66; p=0.12), although this remains hypothesis-generating.
My takeaway: PERISCOPE II does not support routine CRS-HIPEC in this setting. But the results have to be interpreted qith caution.
What are your thoughts?”

You can also read: PERISCOPE II: Gastrectomy, Cytoreductive Surgery, and HIPEC Do Not Improve Survival in Gastric Cancer With Limited Peritoneal Metastases
